Artificial Intelligence driven Marketing Communications
Leveraging the extensive knowledge of GSK’s Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.
Max has invested in over 30 high-tech companies – including DanioLabs (Summit), Novacta, Phonetic Arts (Google), Revieworld, Quotient (EKF), Veebeam, and Transversal – and currently sits on the boards of Grapeshot, Moviestorm, OnRelay, and Power Challenge.
He started his career in Millicom and then Metrosvyaz, both private equity players investing in mobile telecoms companies in Eastern Europe and other emerging markets.
He holds a BSc in Economics from the University of Maryland and an MBA from the University of Cambridge.
Chief Executive at Novacta Biosystems